The EU Commission publishes its 5th patent monitoring report

DG Competition of the European Commission just published its 5th patent monitoring report. It covers patent settlements entered into in 2013. Each year, the Commission claims that the report shows a “steady increase” of patent settlements in general, which supposedly would prove that the Commission’s threat of vigorous enforcement against so-called reverse patent settlements does not prevent pharmaceutical companies from settling patent disputes. The Commission also claims a steady decrease of “problematic settlements”, namely those including a value transfer and a limitation of the generic’s ability to enter the market immediately with its own product. We published a client alert last year warning that the Commission’s conclusions were unsound. The criticism equally applies to this year’s

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • General Court of the European Union (Luxembourg)
  • White & Case (Brussels)
  • White & Case (Brussels)
  • White & Case (Brussels)

Quotation

Ian Forrester, James Killick, Mark D. Powell, Jérémie Jourdan, The EU Commission publishes its 5th patent monitoring report, 5 December 2014, e-Competitions Bulletin December 2014, Art. N° 73803

Visites 215

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues